Artelo Biosciences Inc

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded by James Manley on May 2, 2011 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) --   Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the LD Micro conference which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California.

Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th

SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel, Miami FL. The conference will include virtual and in-person participation.

Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th

SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.

Artelo Biosciences to Present at MicroCap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023

Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Solana Beach, California--(Newsfile Corp. - April 26, 2022) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo, will present at The Q2 Investor Summit, hosted by the Investor Summit Group, being held on May 3-4, 2022 at The Westin New York Grand Central.Event: The Q2 Investor Summit GroupDate: ...

Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York

Artelo Biosciences Inc (NASDAQ: ARTL) says its ART27.13 shows promising preclinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia) via a CB2 mediated mechanism of action. ART27.13 is a peripherally selective G-Protein Coupled.

Artelo Shares Jump On Favorable Preclinical Data In Cancer-Related Muscle-Wasting Syndrome

Cybin

Meten Holding Group Ltd.

ProQR Therapeutics

Sonnet BioTherapeutics

Statera Biopharma Inc

Exela Technologies

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13 New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13

Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia

New Potential Uses of ART26.12 for Treating Tumors New Potential Uses of ART26.12 for Treating Tumors

Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer

SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced it has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th

Reports $25.6 Million in Cash and Marketable Securities as of December 31, 2021, Expected to Support Operations Into Second Half of 2023 Reports $25.6 Million in Cash and Marketable Securities as of December 31, 2021, Expected to Support Operations Into Second Half of 2023

Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update

Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia.

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the Company received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/835,383 entitled “Solid Forms of Cannabidiol and Uses Thereof” related to its ART12.11 program, a cocrystal composition of cannabidiol (CBD). In addition, the Company has pending foreign patent applications covering cocrystal composition-of-matter and method of use.

Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol

Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022

Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom's Home Office has classified the Company's lead clinical cannabinoid, ART27.13, as “non-controlled” and, therefore, is no longer considered a Schedule 1 controlled substance, which would impose limitations on its production, possession, and supply. The Home Office is the lead government department tasked with major economic, security and safety policies, including drug policy.

Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom

Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright Conference Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright Conference

Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference

Here is how Artelo Biosciences, Inc. (ARTL) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.

Is Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?

$26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023 $26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023

Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update

Solana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present as follows: Ev

Artelo Biosciences to Present at the Q4 Investor Summit on November 17th

Baosheng Media Group Holdings

Senseonics Holdings

Are these penny stocks on your watchlist this week? The post Best Penny Stocks to Watch in Mid-November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch in Mid-November 2021

Concert Pharma

TDH Hlds

Check these trending penny stocks out for your watchlist The post Are These Trending Penny Stocks Worth Buying at Current Levels? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Trending Penny Stocks Worth Buying at Current Levels?

ABVC BioPharma

Farmmi

Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Reddit Penny Stocks to Watch That Exploded Today

The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) increased by over 60% pre-market today. This is why it happened.

ARTL Stock: Why The Price Surged Today

Artelo Biosciences, Inc. (ARTL) Q3 2021 Results - Earnings Call Transcript

Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will present at the Q3 Virtual Investor Summit, hosted by the Investor Summit Group, being held virtually on August 17-18, 2021.Andrew Yates, PhD, Senior Vice President and Chief Scientific Officer is scheduled to present as follows. Randy...

News for Artelo Biosciences Inc Stock (ARTL)